Alkermes (ALKS) a mid-cap drugmaker that lacks any notable open interest but the daily chart showing impressive relative strength setting up a bull consolidations after a high-volume surge in early February. ALKS is also clearing a multi-year weekly range and has a 1.382 Fibonacci extension target at $38.25. The company’s next-generation orexin has a potentially best-in-class profile and over $1.5B in sales, and it could provide visibility to longer-term growth for Alkermes. The upcoming Phase 2 data for ALKS-2680 in narcolepsy type 1 and type 2 studies could generate positive results with strong efficacy but safety results will be the focus.